Last week we talked about finding ways to make the T cells work harder and smarter – there are numerous ways to do this, but cytokines might be one interesting way to begin the search.
What about NK and other immune cells though, can we do the same with these too?
This week we are focusing on various cell therapy approaches with some academic and industry interviews to share, along with some analysis of arising issues as well as some new developments to review and discuss.
In the first of the series, we have an academic thought leader in the spotlight who had a few interesting points to make on novel cell therapies…
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the AACR meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
Yesterday we looked at ten innovative approaches centred around T cell-based developments emerging from the American Society of Hematology (ASH) meeting that is taking place in Orlando next month.
Let’s not forget, however, that there are also other immune cells, including NK cells and quite a few others, which can be manipulated into cancer therapeutics for the treatment of hematologic malignancies.
Some of these are intriguing early preclinical research that may form next generation technologies in the future, while others take the form of up and coming early clinical data that readers may be interested to learn more about.
Here we highlight nine emerging immunotherapy approaches to consider that don’t involve T cells…
Curious to find out more about these novel ideas or iterations and get a heads up on insights from our ASH19 commentary? Subscribers can log-in or you can click to gain access to BSB Premium Content.